Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of dazukibart in idiopathic inflammatory myopathies (DM/PM)
CTR20243656Phase 3Active
- Sponsor
- Pfizer
- Start
- Feb 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of dazukibart in Autoimmune Myopathies, dermatomyositis (DM), polymyositis (PM), sponsored by Pfizer. Started Feb 2025; status: active.
02
Drugs
dazukibart
03
Conditions
Autoimmune Myopathiesdermatomyositis (DM)polymyositis (PM)
Beyond the preview
Go deeper on CTR20243656.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20243656.